MAI Capital Management Trims Stock Position in Becton, Dickinson and Company $BDX

MAI Capital Management trimmed its holdings in Becton, Dickinson and Company (NYSE:BDX) by 17.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 26,960 shares of the medical instruments supplier’s stock after selling 5,665 shares during the period. MAI Capital Management’s holdings in Becton, Dickinson and Company were worth $5,046,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. Empowered Funds LLC increased its holdings in Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 1,354 shares in the last quarter. United Bank raised its holdings in shares of Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after buying an additional 993 shares during the period. Wealthfront Advisers LLC raised its stake in shares of Becton, Dickinson and Company by 67.5% during the second quarter. Wealthfront Advisers LLC now owns 13,330 shares of the medical instruments supplier’s stock valued at $2,296,000 after purchasing an additional 5,370 shares during the period. Finally, Ashton Thomas Private Wealth LLC lifted its holdings in Becton, Dickinson and Company by 55.1% in the 2nd quarter. Ashton Thomas Private Wealth LLC now owns 4,838 shares of the medical instruments supplier’s stock worth $833,000 after buying an additional 1,718 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on BDX shares. Bank of America upped their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Morgan Stanley upped their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Barclays started coverage on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price objective on the stock. JPMorgan Chase & Co. decreased their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research note on Tuesday, February 10th. Finally, TD Cowen raised their price target on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $195.46.

Becton, Dickinson and Company Stock Down 2.5%

BDX opened at $176.49 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The company has a market capitalization of $50.25 billion, a PE ratio of 28.79, a P/E/G ratio of 13.12 and a beta of 0.25. The stock’s fifty day moving average is $196.07 and its 200-day moving average is $192.20. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same period in the previous year, the company earned $3.43 earnings per share. Becton, Dickinson and Company’s revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is presently 68.52%.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase plan on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

Insider Activity at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,416 shares of company stock valued at $675,557. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.